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Abstract
Background: The aim herein, was to assess predictors and current trends of radiation 
exposure and total contrast amount use in patients treated with percutaneous coronary 
intervention within chronic total occlusion (CTO PCI) and non-CTO PCI. 
Methods: Based on a nationwide registry (ORPKI), 535,857 patients treated with PCI 
between 2014 and 2018 were analysed. The study included 12,572 (2.34%) patients treated 
with CTO PCI. The CTO PCI and non-CTO PCI groups were compared before and after 
propensity score matching (PSM). Multifactorial mixed regression models were used to assess
predictors of contrast amount use and radiation exposure. 
Results: The mean total contrast dose and radiation exposure decrease reached statistical 
significance in following years for the CTO PCI (p = 0.002 and p < 0.001) and non-CTO PCI 
groups (p < 0.001 and p < 0.001). Multifactorial analysis revealed that non-CTO PCI was a 
strong independent predictor of lower total contrast dose (estimate: –17.41; 95% confidence 
interval [CI]: –18.45 to –16.49, p < 0.001) and radiation exposure (estimate: –264.28; 95% 
CI: –273.75 to –254.81, p < 0.001). After PSM, it was confirmed that CTO PCI was an 
independent predictor of greater radiation exposure (estimate: 328.6; 95% CI: 289.1–368.1; p 
< 0.001) and total contrast dose (estimate: 30.5; 95% CI: 27.28–33.74; p < 0.001). 
Conclusions: Contrast dose and radiation exposure have decreased in previous years with 
regard to the CTO PCI and non-CTO PCI groups. CTO PCI was found to be an independent 
predictor of greater total contrast dose and radiation exposure in the overall group of patients 
treated with PCI. 
Key words: contrast dose; chronic total occlusion, percutaneous coronary intervention, 
radiation exposure
Introduction
The incidence of percutaneous coronary interventions within chronic total occlusion 
(CTO PCIs) in the overall group of examined patients treated with PCI is estimated to be 
between 5.5% and 12% according to the registry, the incidence of CTOs in the overall group 
of patients undergoing coronary angiography ranges between 15% and 20%, however, in 
selected analyses, it reaches even more than half of the values presented for diagnostic heart 
catheterization [1–6]. The frequency of CTOs depends, among others, on the definition of 
CTO or mode of diagnostic coronary angiography. It is estimated that from the group of 
patients with CTO diagnosed during coronary angiography, roughly, 1/3 of them will undergo 
an attempt of CTO PCI (10%) or surgical revascularization (20%) [4]. According to the 
current European guidelines, percutaneous revascularization of CTOs should be considered in
patients with angina resistant to medical therapy or with a large area of documented ischemia 
within the territory of the occluded artery (class IIa B) [7]. A large percentage of patients 
remain under pharmacological therapy due to limited evidence regarding the risk/benefit ratio 
and asymptomatic coronary atherosclerosis [8]. In recently published studies, it has been 
confirmed that there is superiority of PCI over medical therapy in patients with CTO [9, 10]. 
Variability in the frequency of CTO PCIs was observed according to the volume of the center 
[4]. Percutaneous revascularization of CTOs is associated with an increased risk of specific 
procedure-related complications, including those vascular — with leading coronary artery 
perforation, and with longer procedure time of contrast-induced nephropathy (CIN), radiation 
exposure as well as loss of collateral circulation [3, 11]. 
Therefore, in the present study, the aim was to assess predictors and current trends of 
radiation exposure and total contrast amount use in an overall group of patients treated with 
PCI and with special insight into CTO PCIs. 
Methods
Study design and patient population
This retrospective analysis was performed on prospectively collected data [12]. Data 
for conducting the current study were obtained from the National Registry of Percutaneous 
Coronary Interventions (ORPKI), maintained in cooperation with the Polish Cardiac Society’s
Association of Cardiovascular Interventions (AISN). The registry has been described in 
previously published papers [12, 13]. Data were obtained from the registry between January 
2014 and December 2018. 12,572 patients treated with PCI within CTO were selected out of 
535,857 patients treated using PCI during the analyzed period. The technical aspects of the 
procedure, such as the choice of access site (femoral or radial), culprit lesion approach 
(antegrade or retrograde), sheath and catheter size, as well as guidewires, microcatheters and 
other devices specific for CTO PCIs, were at the operator’s discretion. Furthermore, the 
periprocedural anticoagulation and indications for PCI as well as stent type remained at the 
first operator’s discretion. Antiplatelet therapy was initiated according to current European 
guidelines [14]. The protocol complied with the 1964 Declaration of Helsinki, and all 
participants provided their written informed consent to participate in the percutaneous 
intervention. Due to the retrospective nature and anonymisation of the collected data and 
registry, obtaining the consent of the Bioethics Committee was not required.
Study endpoints
Primary study endpoints included the total amount of contrast used during the 
procedure and entire radiation exposure in following years assessed in the presented study. 
Prior to propensity score matching (PSM), predictors of contrast amount and radiation dose in
the overall group of patients treated with PCI were calculated. After PSM, the effect of PCI 
within CTO on the total amount of contrast used during the PCI and whole radiation exposure
was also assessed. 
Statistical analysis
Categorical variables are presented as numbers and percentages. Continuous variables 
are expressed as mean (standard deviation [SD]) or median (interquartile range [IQR]), where 
applicable. Normality was assessed via the Shapiro-Wilk test. Equality of variance was 
evaluated using Levene’s test. Differences between the two groups were compared using the 
Student or Welch t-test, depending on the equality of variance for normally distributed 
variables. The Mann-Whitney U-test was applied for non-normally distributed continuous 
variables. Categorical variables were compared using the Pearson chi-squared or the Fisher 
exact test if 20% of the cells had an expected count of less than 5 (Monte Carlo simulation for
the Fisher test was used with tables of greater dimensions than 2 × 2). All of the 
baseline/demographic characteristics included in the logistic regression model used PSM. 
PSM was performed with the nearest neighbour algorithm. The groups were considered 
balanced if standardised differences for each of the analyzed baseline/demographic 
characteristics were lower than 10%. The PSM analysis included age, body mass, diabetes, 
prior stroke, prior myocardial infarction, prior PCI, prior coronary artery by-pass grafting, 
smoking status, arterial hypertension, kidney disease, chronic obstructive pulmonary disease, 
vascular access, thrombectomy, rotablation use, thrombolysis in myocardial infarction (TIMI),
flow grade prior to PCI, gender, clinical presentation at baseline, cardiac arrest before 
admission to the hospital, the use of imaging tests (fractional flow reserve [FFR], 
intravascular ultrasound [IVUS], optical coherence tomography [OCT]), the results of 
coronary artery angiography, type of PCI and culprit lesion. The effect of PCI within CTO on 
contrast use and radiation exposure was assessed using mixed-effect models to account for 
matching. Statistical analysis was performed using the R, version 3.5.3 (R Foundation for 
Statistical Computing, Vienna, Austria, 2019) with the following packages: ‘MatchIt’, version
3.0.2 and ‘lme4’, version 1.1-21.
Results
Population
Before PSM, a group of 523,128 patients treated with PCI and within the non-CTO 
culprit lesion were compared with 12,569 patients treated within the CTO culprit lesion. 
Patient characteristics
Patients from the CTO group were characterized by significantly younger mean age 
(66.6 ± 10.3 years vs. 67.1 ± 10.8 years, p < 0.001) and a greater occurrence of males (75% 
vs. 67.7%, p < 0.001). This and other clinical indices are presented in Table 1. 
Coronary angiography and culprit lesion characteristics
The frequency of patients with multi-vessel disease (MVD) and without left main 
coronary artery (LMCA) disease involvement, as well as patients with MVD and LMCA 
involvement was more frequent in the CTO group (53.7% vs. 47.7%; 5.9% vs. 5.3%, 
respectively, p < 0.001). These and other variables are presented in Table 2. 
Procedural indices
Patients from the CTO group were more often treated from femoral approach in 
comparison to the non-CTO group (34.6% vs. 24.9%, p < 0.001). Drug-eluting stents (DESs) 
were implanted significantly more often in the non-CTO group (44.9% vs. 85.4%, p < 0.001). 
Those and other procedural indices are presented in Table 3. 
Contrast amount and radiation exposure
Before PSM, mean radiation exposure (1658 ± 1,269.7 vs. 1,031.1 ± 939.5 mGy, p < 
0.001) and the total contrast amount (213.4 ± 102.7 vs. 171.9 ± 75.6 mL, p < 0.001) was 
greater in the CTO group in comparison to non-CTO (Table 3). When considering trends in 
total contrast amount use at the assessed period of time (2014–2018), a significantly higher 
use of total contrast amount in the CTO compared to the non-CTO group in subsequent years 
of the analysed period (p < 0.001) was observed,  while a significant decrease was noted in 
recent years for the CTO (p = 0.002) and non-CTO groups (p < 0.001, Fig. 1A). A similar 
trend was observed for radiation exposure, which has significantly decreased in recent years 
among the CTO (p < 0.001) and non-CTO groups (p < 0.001), and was significantly greater in
subsequent years for the CTO group (p < 0.001, Fig. 1B).
Catheterisation laboratory and operator volume
The total number of catheterization laboratories (CathLab) performing PCI within 
CTO was 164. The average number of CTO procedures per 1 CathLab was: 112 ± 133 (64 [28
÷ 139], range 0–602). The average % of CTO procedures per 1 CathLab was: 2.35 ± 2.16 
(1.85 [0.67÷ 3.1], range 0–11.71). Total radiation exposure per 1 procedure was not correlated
with number of procedures per 1 CathLab (R = 0.017) or with the % of procedures (R = 
0.025).
Total contrast dose per 1 procedure was neither correlated with number of procedures 
per 1 CathLab (R = 0.042) nor with the % of procedures (R = 0.034). The number of operators
was not available in the presented analysis.
Propensity score matching
A comparison of selected indices between the CTO and non-CTO groups after PSM is 
presented in Table 4. 
Predictors of increased radiation dose and contrast amount
Predictors of contrast amount used during PCI are presented on the Figure 3, while 
predictors of radiation exposure are presented on Figure 4. Following PSM, PCI within the 
CTO lesion remained significantly correlated with the increased total use of contrast amount 
(estimate: 30.5, 95% CI: 27.28–33.74; p < 0.001) and greater radiation exposure (estimate: 
328.6, 95% CI: 289.1–368.1; p < 0.001). 
Discussion
The main finding of the current study was that over subsequent years, the total contrast
amount and radiation exposure remained significantly higher in CTO PCI group in 
comparison to the non-CTO PCI group. Moreover, the total contrast dose and radiation 
exposure decreased significantly in following years in the CTO PCI as well as non-CTO PCI 
groups. Among several predictors, CTO PCI was an independent one of greater total contrast 
amount and radiation exposure in the overall group of patients treated with PCI. Importantly, 
after PSM, between the CTO PCI and non-CTO PCI groups, the former was still a significant 
predictor of greater total contrast amount use and radiation exposure.
Contrast amount
In the presented analysis, it was found that concomitant kidney disease is related to the
lower use of contrast during PCI in the overall group of patients, which seems to be justified 
by greater probability of kidney failure and greater consideration of the operators paid to the 
amount of contrast used during PCI. A similar relationship was observed for chronic 
obstructive pulmonary disease and prior PCI. The presence of diabetes was found to be 
related to the greater amount of contrast use during the PCI procedure, which may be 
explained by more disseminated atherosclerosis and potentially more complicated procedures.
Moreover, lack of patency before PCI expressed as TIMI grade flow 0, the presence of no-
reflows and the use of more complicated imaging devices (FFR/IVUS/OCT) were indicative 
of greater contrast use amounts. No-reflows demand longer procedures and multiple cine 
angiographies after infusion of particular agents in the treatment of coronary flow 
disturbances. PCI within occluded arteries at baseline is usually related to more complicated 
and longer procedures. Furthermore, PCI within restenosis is found to be a predictor of 
increased risk regarding higher contrast use in comparison to de-novo lesions, which seems to
be reasonable in terms of the degree of procedure difficulty. A similar relationship and 
explanation could be dedicated to thrombosis in comparison to de-novo culprit lesions. 
Femoral access usually concerns the use of greater guiding catheter diameters, potentially 
more complicated procedures or patients in more severe states. The relationship between body
mass, as well as the dose of contrast and radiation, is well-sanctioned and requires no 
additional comments.
In the study published by Michael et al. [15], which included 1,363 consecutive CTO 
PCIs, performed at 3 institutions between January 2006 and November 2011, CTOs within the
coronary arteries were defined as angiographic evidence of total occlusion with TIMI grade 0 
or 1 and an estimated duration of at least 3 months [15]. The authors of that analysis 
confirmed that prior coronary artery bypass grafting, right coronary artery target vessel, fewer
years since initiation of CTO PCI registry at each center, use of the retrograde approach and 
procedural failure, were independently associated with prolonged fluoroscopy duration [15]. 
In the study published by Michael et al. [15], the mean contrast amount used during 1 CTO 
PCI totaled 294 ± 158 mL and 265 mL. This was a significantly greater amount when 
compared to the present results and may be related to earlier years of the conducted analysis. 
At that time, similar results could be noticed in our population. Morino et al. [16], in their 
study based on the Multicenter CTO Registry in Japan, reported the median contrast volume 
per 1 CTO PCI to be 293 mL while CIN frequency was at 1.2%. In a more recently published 
study, based on the PROGRESS-CTO registry, the results were comparable to those obtained 
in the present analysis [17]. While Konstantinidis et al. [18] reported the mean contrast 
volume in patients treated with CTO PCI, based on the 17,626 procedures from the European 
Registry of CTO at following periods of time, to be: 298 mL (2008–2009), 298 mL (2008–
2009), 310 mL (2012–2013) and 280 mL (2014–2015). In another publication from the 
Japanese CTO-PCI Expert Registry, similar data to that obtained in the currently presented 
analysis was also reported [19].
Radiation exposure
Assessing predictors of radiation exposure in the overall group of patients treated with 
PCI in the present study, it was demonstrated that diabetes, kidney disease and femoral access 
are predictors of increased radiation exposure. Diabetes and kidney failure are usually related 
to more complicated, calcified and long-narrow arteries, which undoubtedly increase the 
difficulty of the procedure and are related with the use of additional devices such as 
rotablation. Also, the no-reflow phenomena and TIMI flow grade 0 were among predictors of 
greater radiation exposure, which could be related to a longer procedure duration. Considering
the type of PCI, PCIs with bare-metal stent and bioresorbable scaffold implantation were 
predictors of greater radiation exposure when compared to DES implantation. The presence of
CTO PCI was the strongest predictor among all the estimated indices of greater radiation 
exposure during the PCI procedure. This was also confirmed following PSM. 
The median patient air kerma dose reported in a recently published study, which was 
based on the PROGRESS_CTO registry, was greater when compared to the current study and 
was 2.642 Gy for the years 2012–2019, 2.825 Gy for 2012–2016 and 2.382 Gy for 2017–2019
[17]. In a recent report from the European Registry of CTO, rather stable mean fluoroscopy 
durations are shown at the following assessed periods: 37 min (2008–2009), 49 min (2010–
2011), 43 min (2012–2013) and 43 min (2014–2015) [18]. However, this can lead to 
erroneous conclusions, because nowadays, devices with lower radiation and lower frame rates
are used, which in summary, allows implementation of radiation doses more slowly.
Preventive actions
Contrast-induced nephropathy (CIN), a common complication following PCI, is the 3rd
most common cause of acute renal failure in patients admitted to hospital, and it is associated 
with increased morbidity, mortality and medical costs [20]. Administration of higher contrast 
volumes is associated with higher risks of contrast nephropathy, and CTO PCI has been 
connected with high contrast volume administration [16, 21]. In a meta-analysis published by 
Patel et al. [22], the incidence of CIN was reported to be between 2.4% and 18.1%, with a 
pooled estimate rate of 3.4%. Therefore, all treatments applied in order to reduce the supply 
of contrast dose are highly desirable. Among several possible interventions aimed at contrast 
reduction, radial and biradial access were found to be superior over femoral access [23]. 
Special devices for contrast dosing during PCI have also been developed, the use of which has
been proven to reduce the volume of contrast administered in patients undergoing PCI within 
CTO [24]. Recently, descriptions have also been published of successful attempts to perform 
PCI procedures within CTO, using gadolinium in combination with IVUS among patients 
with anaphylaxis to iodinated contrast agents [25]. 
In the case of increased radiation during PCI, we are mainly concerned with short-term
effects such as radiation-induced dermatitis, as well as distant consequences, e.g. related to 
bone marrow damage or oncological diseases. Radiation dermatitis is the most common direct
complication of high radiation exposure in CTO PCIs, and being a rare complication, in some 
publications, no such events have even been reported [16]. Recently, many factors have 
contributed to a decrease in radiation exposure during PCI and especially, CTO PCI. One of 
the 1st statement documents which was published in 2011, recommended the use of 7.5 frames
per 1 second of fluoroscopy [26]. Furthermore, other additional modifications are available 
and include increased copper filtering with lower entry dose in combination with modified 
post-processing image [27]. Nowadays, including the current centre, 4 frames per second of 
fluoroscopy is mostly used. Among other recommendations advised in the document were: 
limiting the use of cine angiography and applying the “fluoro-store” function instead; 
optimizing the position of the table and image intensifier; rotating the image intensifier to 
distribute radiation exposure to multiple skin entry sites; using shielding; closely monitoring 
radiation exposure throughout the duration of the procedure; and terminating the procedure if 
a pre-defined threshold is reached without successful lesion crossing [26]. In older studies, it 
has been reported that CTO PCIs, compared to non-CTO, are related to as much as 40% 
higher radiation exposure [28]. Currently, it is clearly visible in the presented analysis that this
difference remains similar, besides the fact that the overall radiation exposure permanently 
and statistically significantly decreased in following years among the CTO PCI and non-CTO 
PCI groups. It has been demonstrated that modern X-ray equipment enables introduction of 
modified protocols aimed at a drastic reduction of the fluoroscopy exposure [29]. Another 
factor proven to be related with lower radiation exposure was biradial vascular access [23].
Strengths and limitations of the study
The greatest strength of the presented study is the large number of examined patients, 
as analyses carried out among such numerous patient groups s with CTO are rare. However, 
from a number of limitations of the current study, those that should be addressed in the first 
place include the nature of the analysis. The research was retrospective, carried out on the 
basis of a prospectively collected registry. Many of the disadvantages of such a registry 
include, but are not limited to, estimating the frequency of periprocedural complications 
arising from the registry itself, which further include complications only during the time of 
procedure and the early post-procedural period when the patient is still at the catheterisation 
laboratory. This enables assessment of the number of patients with contrast-induced 
nephropathy or radiation dermatitis. Another important issue is that recognising the culprit 
lesion as CTO was at the discretion of the operator and depended on his/her knowledge, 
habits or inclinations, which, unfortunately, imposes bias. Other well-recognized predictors of
contrast dose or radiation exposure in the current analysis was not possible to include because 
the analyzed database did not contain such data. These would include such parameters as 
culprit lesion characteristics (length, diameter, location, tortuosity, extent of calcification, 
etc.), type of devises used for PCI (guidewires, microcatheters as well as type of vascular 
approach: retrograde vs. antegrade), number of prior attempts to perform CTO PCI. These 
missing values could have significantly modified the results and caused some bias. In the 
presented analysis, the relationship between operator volume and contrast amount or radiation
exposure was also not taken into consideration due to a lack of data. It may be expected that 
more experienced operators use less contrast and radiation exposure.
Conclusions
Total contrast amount and radiation exposure remain significantly higher in CTO PCI 
compared to non-CTO PCI in subsequent years assessed in the current analysis. The total 
contrast dose and radiation exposure decreased statistically significantly in following years for
the CTO PCI as well as the non-CTO PCI groups. Among several predictors, CTO PCI was 
found to be an independent one of greater total contrast amount dose and radiation exposure 
in the overall group of patients treated with PCI. After propensity score matching analysis 
between the CTO PCI and non-CTO PCI groups, CTO PCI was also confirmed as a 
significant predictor of greater total contrast amount and radiation exposure. Although the 
difference between the volume of contrast and radiation dose remains significant for CTO and
non-CTO PCI, in both groups, the contrast dose and radiation exposure have decreased in 
recent years, which means that these actions aimed at their reduction are effective, but still 
require attention and improvement in many patients to decrease the incidence of preventable 
complications related to CTO PCI.
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Table 1. Clinical characteristics at baseline for patients treated with PCI according to culprit lesion type — CTO vs. non-CTO.
Variables Total (n = 535,853) Non-CTO (n = 523,281) CTO (n = 12,572) P
Age, years 67.1 ± 10.8 67.1 ± 10.8 66.6 ± 10.3 < 0.001
Weight [kg] 80.9 ± 16.9 80.9 ± 16.9 83.2 ± 16.1 < 0.001
Gender, male 363,574 (67.9) 354,147 (67.7) 9,427 (75) < 0.001
Diabetes 127,441 (23.8) 123,969 (23.7) 3,472 (27.6) < 0.001
Arterial hypertension 378,874 (70.7) 369,259 (70.6) 9,615 (76.5) < 0.001
Prior stroke 17,507 (3.3) 17,015 (3.2) 492 (3.9) < .001
Prior myocardial infarction 163,353 (30.5) 157,452 (30.1) 5,901 (46.9) < 0.001
Prior PCI 198,339 (37) 192,360 (36.8) 5,979 (47.6) < 0.001
Prior CABG 33,167 (6.2) 32,133 (6.1) 1,034 (8.2) < 0.001
Smoking 106,123 (19.8) 103,412 (19.8) 2,711 (21.6) < 0.001
Kidney failure 29,487 (5.5) 28,552 (5.5) 935 (7.4) < 0.001
COPD 11,623 (2.6) 11,214 (2.6) 409 (3.7) < 0.001
Clinical presentation of CAD < 0.001
Stable angina 155,651 (29.1) 149,347 (28.6) 6,304 (50.3)
Unstable angina 155,141 (29.0) 152,163 (29.1) 2,978 (23.7)
NSTEMI 100,989 (18.8) 99,374 (19.0) 1,615 (12.9)
STEMI 116,617 (21.8) 115,197 (22.1) 1,420 (11.3)
Others 6772 (1.3) 6541 (1.2) 231 (1.8)
Data are presented as mean ± standard deviation or count (percentage); percentages reflect available study data.  
CTO — chronic total occlusion; CABG — coronary artery by-pass grafting; COPD — chronic obstructive pulmonary disease; CAD — coronary 
artery disease; NSTEMI —  non-ST segment elevation myocardial infarction; PCI — percutaneous coronary intervention; STEMI — ST segment
elevation myocardial infarction
Table 2. Coronary angiography and culprit lesion characteristics among patients treated with PCI according to coronary artery patency (CTO vs. 
non-CTO).
Variables Total (n = 535,853) Non-CTO (n = 523,281) CTO (n = 12,572) P
Coronary angiography < 0.001
SVD 206,117 (46.6) 202,713 (46.7) 3,404 (40.2)
MVD without  LMCA 211,418 (47.8) 206,868 (47.7) 4,550 (53.7)
MVD and LMCA 23,652 (5.3) 23,152 (5.3) 500 (5.9)
Isolated LMCA 1,156 (0.3) 1,142 (0.3) 14 (0.2)
Location of culprit artery
Right coronary artery 156,296 (31.6) 150,884 (31.4) 5,814 (46) < 0.001
Left main coronary artery 16,009 (3.2) 15,819 (3.3)  64 (0.5) < 0.001
Left anterior descending artery 186,974 (37.8) 183,150 (38.1) 3,811 (30.2) < 0.001
Circumflex artery 124,025 (25.1) 122,058 (25.4) 2,841 (22.5) < 0.001
Intermediate artery 8,519 (1.7) 8,376 (1.7) 100 (0.8) < 0.001
Bifurcation 9,410 (8.3) 9,248 (8.3) 162 (6.0) < 0.001
Type of culprit lesion < 0.001
De-novo 440,847 (94.03) 430,301 (94.05) 10,546 (93.6)
Restenosis: 25,256 (5.39) 24,559 (5.37) 697 (6.19)
   Drug-eluting stent 17,344 (3.70) 16,895 (3.69) 449 (3.99)
   Bare-metal stent 6,743 (1.44) 6,521 (1.43) 222 (1.97)
   Bioresorbable scaffold 252 (0.05) 248 (0.05) 4 (0.04)
   Drug-coated balloon 560 (0.12) 546 (0.12) 14 (0.12)
   Plain-old balloon angioplasty 357 (0.08) 349 (0.08) 8 (0.07)
In-stent thrombosis 2,710 (0.58) 2,686 (0.59) 24 (0.21)
Data are presented as count (percentages); percentages reflect available study data. 
CTO — chronic total occlusion; LAD — left anterior descending coronary artery; LMCA — left main coronary artery; MVD — multi-vessel 
disease; PCI — percutaneous coronary intervention; SVD — single-vessel disease 
Table 3. Procedural indices among patients treated with PCI according to coronary artery patency of (CTO vs. non-CTO).
Variables Total (n = 535,853) Non-CTO (n = 523,281) CTO (n = 12,572) P
Vascular access, femoral 133,364 (25.1) 129,055 (24.9) 8,153 (34.6) < 0.001
Fractional flow reserve 10,355 (1.9) 10,224 (1.9) 131 (1.0) < 0.001
Intravascular ultrasound 6,442 (1.2) 6,263 (1.2) 179 (1.4) 0.02
Optical coherence tomography 992 (0.2) 912 (0.2) 80 (0.6) < 0.001
Rotablation 2,710 (0.5) 2,604 (0.5) 106 (0.8) < 0.001
TIMI flow grade before PCI < 0.001
0  107,446 (20.8) 97,656 (19.4) 9,970 (78.7)
Other than 0 408,776 (79.2) 406,128 (80.6) 2,648 (21.3)
TIMI flow grade after PCI < 0.001
0 11,712 (2.3) 7,799 (1.5) 3,913 (31.5)
1 5,419 (1) 4,737 (0.9) 682 (5.5)
2 14,896 (2.9) 14,372 (2.9) 524 (4.2)
3 484,862 (93.8) 477,547 (94.7) 7,315 (58.8)
Culprit artery patency after PCI < 0.001
Absent  (TIMI grade 0 and 1) 17,131 (3.3) 12,536 (2.5) 4,595 (36.7)
Present (TIMI grade 2 and 3)  499,758 (96.7) 491,919 (97.5) 7,839 (63)
Type of PCI < 0.001
Drug-eluting stent 452,793 (84.5) 447,148 (85.4) 5,645 (44.9)
Bare-metal stent 21,265 (4.0) 21,243 (4.1) 22 (0.2)
Bioresorbable stent 4,574 (0.8) 4,280 (0.8) 294 (2.3)
DCB/POBA/Failed angioplasty 57,220 (10.7) 50,609 (9.7) 6,611 (52.6)
Procedural related complications 10,462 (1.95) 10,115 (1.93) 346 (2.75) < 0.001
Radiation dose [mGy] 1045.4 ± 952.9
789 [446 ÷ 1340]
1,031.1 ± 939.5
780 [441 ÷ 1321]
1658 ± 1269.7
1334 [765 ÷ 2188]
< 0.001
Contrast amount [mL] 172.8 ± 76.8
150 [120 ÷ 200]
171.9 ± 75.6
150 [120 ÷ 200]
213.4 ± 102.7
200 [150 ÷ 250]
< 0.001
Data are presented as mean ± standard deviation, median [interquartile range] or count (percentage); percentage reflects available study data. 
BMS — bare-metal stent; BRS — bioresorbable scaffold; CTO — chronic total occlusion; DCB — drug-coated balloon; DES — drug-eluting 
stent; FFR — fractional flow reserve; IVUS — intravascular ultrasound; OCT — optical coherence tomography; PCI — percutaneous coronary 
intervention; POBA — plain-old balloon angioplasty; TIMI — thrombolysis in myocardial infarction
Table 4. Comparison between the group of patients treated with PCI after propensity score matching according to culprit lesion type — CTO and
non-CTO.
Non-CTO (n = 5,652) CTO (n = 5,652)
Age 67.2 ± 10.8 67.0 ± 10.4 
Weight [kg] 83.1 ± 16.3 83.4 ± 16.5
Gender, males 4,044 (71.5) 4,173 (73.8)
Diabetes 1,570 (27.8) 1,592 (28.2)
Prior stroke 253 (4.5) 237 (4.2)
Prior myocardial infarction 2,223 (39.3) 2,337 (41.3)
Prior PCI 2,115 (37.4) 2,241 (39.6)
Prior CABG 464 (8.2) 440 (7.8)
Smoking 1,298 (23.0) 1,308 (23.1)
Arterial hypertension 4,214 (74.6) 4,285 (75.8)
Kidney disease 397 (7.0) 407 (7.2)
Chronic obstructive pulmonary disease 251 (4.4) 259 (4.6)
Vascular access, femoral 1,498 (26.5) 1,431 (25.3)
Rotablation 29 (0.5) 28 (0.5)
TIMI flow grade before PCI other than 0 1,207 (21.4) 1,328 (23.5)
Contrast amount [mL] 175.5 ± 79.42 205.7 ±95.2
Radiation dose [mGy] 1,191.4 ±1,000.6 1,521.8 ±1,137.2
Procedure-related complications 256 (4.5) 175 (3.1)
Dissection 23 (0.4) 3 (0.1)
Indication
Stable angina 1,743 (30.8) 2,137 (37.8)
Unstable angina 1,823 (32.3) 1,694 (30.0)
NSTEMI 1,086 (19.2) 985 (17.4)
STEMI 806 (14.3) 676 (12.0)
Others 194 (3.4) 160 (2.8)
Cardiac arrest before admission 140 (2.5) 104 (1.8)
IVUS+FFR+OCT 157 (2.8) 179 (3.2)
Coronary angiography
Single vessel disease 2,116 (37.4) 2,211 (39.1)
MVD – LMCA 3,027 (53.6) 3,006(53.2)
MVD + LMCA 502 (8.9) 427 (7.6)
Separate LMCA 7 (0.1) 8 (0.1)
Type of PCI: () ()
   DES 2,329 (41.2) 2,381 (42.1)
   BMS 13 (0.2) 11 (0.2)
   BRS 115 (2.0) 125 (2.2)
   DCB/POBA/Failed 3,195 (56.5) 3,135 (55.5)
Type of culprit lesion:
   De-novo 5,196 (91.9) 5,233 (92.6)
   Restenosis 441 (7.8) 403 (7.1)
   Thrombosis 15 (0.3) 16 (0.3)
Data are presented as mean ± standard deviation or count (percentage); percentages reflect available study data. 
CTO — chronic total occlusion; BMS — bare-metal stent; BRS — bioresorbable scaffold; CABG — coronary artery bypass grafting; DES — 
drug-eluting stent; FFR — fractional flow reserve; IVUS — intra-vascular ultrasound; LMCA — left main coronary artery; MVD — multi-vessel
disease; NSTEMI — non-ST segment elevation myocardial infarction; OCT — optical coherence tomography; PCI — percutaneous coronary 
intervention; STEMI — ST-segment elevation myocardial infarction; TIMI — thrombolysis in myocardial infarction
Figure 1. A. Mean contrast amount used per 1 percutaneous coronary intervention (PCI) 
procedure in following years (2014–2018), among patients treated within chronic total 
occlusion (CTO) and non-CTO culprit lesions. Each error bar is constructed using a 95% 
confidence interval of the mean; *if p < 0.001 comparing patients in the CTO and non-CTO 
group during individual years; B. Mean radiation dose used per 1 PCI procedure in following 
years (2014–2018), among patients treated within CTO and non-CTO culprit lesions. Each 
error bar is constructed using a 95% confidence interval of the mean; *if p < 0.001 comparing
patients in the CTO and non-CTO group during individual years.
Figure 2. A. Frequency distribution of total contrast volume used during the chronic total 
occlusion (CTO) and non-CTO procedures; B. Frequency distribution of total radiation 
exposure in CTO and non-CTO procedures.
Figure 3. Predictors of increased contrast use in the overall group of patients treated with 
percutaneous coronary intervention (PCI) — before propensity score matching (PSM); BMS 
— bare-metal stent; BRS — bioresorbable scaffold; CI — confidence interval; COPD — 
chronic obstructive pulmonary disease; CTO — chronic total occlusion; DCB — drug-coated 
balloon; DES — drug-eluting stent; FFR — fractional flow reserve; IVUS — intravascular 
ultrasound; LAD — left anterior descending coronary artery; MI — myocardial infarction; 
OCT — optical coherence tomography; POBA — plain-old balloon angioplasty; TIMI — 
Thrombolysis in Myocardial Infarction.
Figure 4. Predictors of increased radiation exposure in the overall group of patients treated 
with percutaneous coronary intervention (PCI) — before propensity score matching (PSM); 
BMS — bare-metal stent; BRS — bioresorbable scaffold; COPD — chronic obstructive 
pulmonary disease; CTO — chronic total occlusion; DCB — drug-coated balloon; DES — 
drug-eluting stent; FFR — fractional flow reserve; IVUS — intravascular ultrasound; LAD —
left anterior descending coronary artery; MI — myocardial infarction; OCT — optical 
coherence tomography; POBA — plain-old balloon angioplasty; TIMI — thrombolysis in 
myocardial infarction.




